1. Short title This Act may be cited as the Fairness for Patient Medications Act . 2. Requirements with respect to cost-sharing for highly rebated drugs (a) PHSA Part D of title XXVII of the Public Health Service Act ( 42 U.S.C. 300gg–111 et seq. ) is amended by adding at the end the following: 2799A–11. Requirements with respect to cost-sharing for highly rebated drugs (a) In general No later than April 1, 2024, and annually thereafter, the Secretary shall certify (or recertify, if applicable) as a highly rebated drug any drug identified in reports submitted under sections 2799A–10, 725 of the Employee Retirement Income Security Act, and 9825 of the Internal Revenue Code of 1986 for which total rebates, reductions in price, and other forms of remuneration in the previous year aggregated across all commercial markets exceeded 50 percent of total annual spending on such drug in such year. (b) Deductible and cost-Sharing limitations for certified drugs For plan years that begin on or after January 1, 2025, a group health plan or a health insurance issuer offering group or individual health insurance coverage (or entity that provides pharmacy benefits management services on behalf of such a plan or issuer) that provides coverage of any highly rebated drug shall not impose cost-sharing in excess of, per 30-day supply, the quotient of the annual net price paid by such group health plan or health insurance issuer (or entity that provides pharmacy benefits management services on behalf of such a plan or issuer), in the most recent calendar year for which a final net price has been calculated by such plan or coverage (or entity that provides pharmacy benefit management services on behalf of such plan or issuer), per 30-day supply of such specific highly rebated drug, divided by 12. (c) Highly rebated drug previously subject to formulary exclusion Beginning on January 1, 2025, in the case of a specific highly rebated drug covered by a group health plan or health insurance issuer offering group or individual health